JEMPERLI in combination with carboplatin and paclitaxel offers meaningful study results

For people with newly-diagnosed advanced or returned endometrial cancer

JEMPERLI + carboplatin and paclitaxel (CP): The FIRST AND ONLY FDA-approved immunotherapy combination proven to help patients with newly-diagnosed advanced or returned endometrial cancer LIVE LONGER.*

*In the overall study population, median overall survival (OS) with JEMPERLI + CP was 45 months vs 28 months with CP alone. This difference is statistically significant, which means that the difference between the 2 treatment groups is greater than what might be expected by chance alone. Median (MEE-de-un) is the middle value in a set of measurements. OS measures the average length of time patients are alive after the start of treatment. JEMPERLI + CP was not studied in comparison to other immunotherapy combinations.

Clinical trial basics for understanding RUBYClinical trial basics for understanding RUBY

Before they are approved, medications are required to undergo rigorous testing through clinical trials. Once you understand how a trial works, you’ll have a better idea of how or if a treatment may work for a patient like you.

 

When scientists have reason to believe that a medication can treat, prevent, or manage a disease, that medication is then studied for potential benefits and risks in a clinical trial. The U.S. Food and Drug Administration (FDA) then reviews data from the trials to determine if the medication will be approved.

What’s actually studied in a clinical trial?

Before the trial begins, scientists plan how the trial will be conducted and what the study will measure. These planned measures are called endpoints (more on that later) and can be used to help learn about the potential benefits and risks of the drug.

Who participates in a clinical trial?

Patients can volunteer to join a trial. Known as study participants, they are selected based on many factors including their type of disease, how severe their disease is, and their overall health.

How JEMPERLI was studied in patients like you

A clinical trial called RUBY compared JEMPERLI + CP versus CP alone in 494 people with endometrial cancer that had spread outside the uterus (newly-diagnosed advanced) or returned, also known as the overall study population. The overall study population included people whose tumors were either dMMR/MSI-H or MMRp/MSS.

 

dMMR stands for “mismatch repair deficient.” It describes cancers that have an MMR system that is not working properly to correct errors in the genes. MSI-H, or microsatellite instability-high, describes unstable genes in some tumors that may occur because the MMR system is not repairing mistakes properly. MMRp, or mismatch repair proficient, describes cancers that have an MMR system that is working properly to correct errors in the genes. MSS, or microsatellite stable, describes cancers that have stable genes because the MMR system is working properly to correct errors in the genes. These are important biomarkers in endometrial cancer.

Study participants taking JEMPERLI + CP received:

500 mg of JEMPERLI + CP every 3 weeks for 6 doses

Then 1000 mg of JEMPERLI alone every 6 weeks

Study participants taking CP alone received:

CP + placebo (an inactive substance designed to look like the medicine being tested) every 3 weeks for 6 doses

Then placebo alone every 6 weeks

    Why this may be important to you

    The RUBY clinical trial tested the effectiveness and safety of adding JEMPERLI to CP. The trial treated some patients with JEMPERLI + CP and others with a placebo (an inactive substance) + CP and then compared the results. Based on the results of this trial, this combination of medications was approved by the U.S. Food and Drug Administration (FDA) and made available for doctors to prescribe to patients.

      Overall population tag

      People receiving JEMPERLI + CP with newly-diagnosed advanced or returned endometrial cancer LIVED LONGER

      Overall survival definitionOverall survival definition

      In the overall study population, median OS with JEMPERLI + CP was 45 months vs 28 months with CP alone. This difference is statistically significant, which means that the difference between the 2 treatment groups is greater than what might be expected by chance alone. Results varied among different biomarker groups within the overall population. Median is the middle value in a set of measurements. JEMPERLI + CP was not studied in comparison to other immunotherapy combinations.

      JEMPERLI + CP significantly extended OS

      JEMPERLI + CP overall survival vs CP alone

      136 out of 245 participants treated with JEMPERLI + CP were still alive, compared with 105 out of 249 treated with CP alone.

      OS gold standard measure bannerOS gold standard measure banner

      People taking JEMPERLI + CP lived a median of 16 MONTHS LONGER than those taking CP alone

      Median (MEE-de-un) is the middle value in a set of measurements.

      Median OS:

      Median OS results for JEMPERLI + CP vs CP alone

      Patients receiving JEMPERLI + CP were significantly less likely to have their cancer grow, spread, or get worse compared to CP alone

      Progression-free survival definitionProgression-free survival definition

      In the overall study population, participants receiving JEMPERLI + CP experienced a median of 12 months without their cancer growing, spreading, or getting worse, compared with 8 months for those on CP alone. This difference is statistically significant, which means that the difference between the 2 treatment groups is greater than what might be expected by chance alone. Results varied among different biomarker groups within the overall population. Median (MEE-de-un) is the middle value in a set of measurements.

      Study participants receiving JEMPERLI + CP were:

      Progression-free survival results for JEMPERLI + CP vs CP alone

      110 out of 245 participants treated with JEMPERLI + CP didn’t experience their cancer growing, spreading, or getting worse, compared with 72 out of 249 treated with CP alone.

      dMMR/MSI-H tag

      People with dMMR/MSI-H biomarker status taking JEMPERLI + CP experienced a median of 30 months without their cancer growing, spreading, or getting worse

      The JEMPERLI clinical trial also measured median progression-free survival (PFS) in people with dMMR/MSI-H tumors. PFS is the length of time that participants experienced without their cancer growing, spreading, or getting worse. Median (MEE-de-un) is the middle value in a set of measurements.

      Median PFS results for people with dMMR/MSI-H biomarker status taking JEMPERLI + CP vs CP alone

      37 out of 60 participants treated with JEMPERLI + CP didn’t experience their cancer growing, spreading, or getting worse, compared with 15 out of 62 treated with CP alone.

      Study participants receiving JEMPERLI + CP were 71% less likely to have their cancer grow, spread, or get worse compared with those receiving CP alone.

      Overall population tag

      Objective response rate for JEMPERLI + CP compared to CP alone

      Objective response rate (ORR): The percentage of people in a study whose tumors partially shrink or disappear in response to the treatment within a certain period of time.

      JEMPERLI + CP:

      Response rates in the RUBY trial for JEMPERLI when given with CP

      This does not always mean that the cancer has been cured.

      CP Alone:

      Response rates in the RUBY trial for placebo when given with CP

      This does not always mean that the cancer has been cured.

      You are not alone

      Endometrial cancer statisticsEndometrial cancer statistics

      About 62,000 cases of endometrial cancer are diagnosed annually in the US

      About 1 in 4 people with endometrial cancer has cancer that has come back after treatment or has spread outside the uterus (advanced cancer)

      What is JEMPERLI?

      JEMPERLI is an immunotherapy. This means it is designed to work with the body’s immune system to help fight cancer.

      What are the side effects of JEMPERLI?

      Certain side effects have been observed in people taking JEMPERLI. While everyone's treatment experience is different, knowing what you may expect can help.

      Resources for you

      Knowledge is power. That’s why we’re committed to providing you with educational resources to help you stay informed along your treatment journey.

      Related FAQs

        Approved Uses & Safety Info

        Approved Uses

        Important Safety Information

        Approved Uses

        JEMPERLI is a prescription medicine used to treat adults with:

        • a kind of uterine cancer called endometrial cancer (EC)
          • JEMPERLI may be used in combination with the chemotherapy medicines, carboplatin and paclitaxel, and then after that JEMPERLI may be used alone:
          • when your cancer has spread outside your uterus (advanced) or,
          • your cancer has returned.
        • JEMPERLI may be used alone:
          • when a laboratory test shows that your tumor is mismatch repair deficient (dMMR), and
          • your cancer has returned, or it has spread (advanced EC), and
          • you have received chemotherapy that contains platinum and it did not work or is no longer working, and
          • your cancer cannot be treated by surgery or radiation.
        • a kind of cancer that is shown by laboratory test to be dMMR solid tumor. JEMPERLI may be used alone to treat:
          • cancer that has returned or has spread (advanced cancer) and,
          • has progressed during treatment or after treatment, and you have no satisfactory treatment options.
          • This use is approved based on how many patients responded to treatment and how long they responded. Studies are ongoing to confirm the clinical benefit of JEMPERLI for this use.

         

        It is not known if JEMPERLI is safe and effective in children.

        Important Safety Information

        JEMPERLI is a medicine that may treat certain cancers by working with your immune system. JEMPERLI can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen anytime during treatment or even after your treatment has ended.

         

        Call or see your healthcare provider (HCP) right away if you develop any new or worsening signs or symptoms, including:

         

        Lung problems. Signs and symptoms may include cough, shortness of breath, or chest pain.

         

        Intestinal problems. Signs and symptoms may include diarrhea or more bowel movements than usual; stools that are black, tarry, sticky, or have blood or mucus; or severe stomach-area (abdomen) pain or tenderness.

         

        Liver problems. Signs and symptoms may include yellowing of your skin or the whites of your eyes, severe nausea or vomiting, pain on the right side of your stomach area (abdomen), dark urine (tea colored), or bleeding or bruising more easily than usual.

         

        Hormone gland problems. Signs and symptoms may include headaches that will not go away or unusual headaches, eye sensitivity to light, eye problems, rapid heartbeat, increased sweating, extreme tiredness, weight gain or weight loss, feeling more hungry or thirsty than usual, urinating more often than usual, hair loss, feeling cold, constipation, your voice gets deeper, dizziness or fainting, changes in mood or behavior such as decreased sex drive, irritability, or forgetfulness.

         

        Kidney problems. Signs and symptoms may include change in the amount or color of your urine, blood in your urine, swelling in your ankles, or loss of appetite.

         

        Skin problems. Signs and symptoms may include rash; itching; skin blistering or peeling; swollen lymph nodes; painful sores or ulcers in your mouth or in your nose, throat, or genital area; fever or flu-like symptoms.

         

        Problems can also happen in other organs and tissues. These are not all of the signs and symptoms of immune system problems that can happen with JEMPERLI. Call or see your HCP right away for any new or worse signs or symptoms. Signs and symptoms may include chest pain, irregular heartbeat, shortness of breath, swelling of ankles; confusion, sleepiness, memory problems, changes in mood or behavior, stiff neck, balance problems, tingling or numbness of the arms or legs; double vision, blurry vision, sensitivity to light, eye pain, changes in eyesight; persistent or severe muscle pain or weakness, muscle cramps; low red blood cells, bruising.

         

        Infusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include chills or shaking, itching or rash, flushing, shortness of breath or wheezing, dizziness, feel like passing out, fever, back or neck pain.

         

        Rejection of a transplanted organ. Your HCP should tell you what signs and symptoms you should report and monitor you, depending on the type of organ transplant that you have had.

         

        Complications, including graft-versus-host-disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be serious and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with JEMPERLI. Your HCP will monitor you for these complications.

         

        Getting medical treatment right away may help keep these problems from becoming more serious. Your HCP will check you for these problems during treatment with JEMPERLI and may treat you with corticosteroid or hormone replacement medicines. If you have severe side effects, your HCP may also need to delay or completely stop treatment with JEMPERLI.

         

        Before receiving JEMPERLI, tell your HCP about all of your medical conditions, including immune system problems such as Crohn's disease, ulcerative colitis, or lupus; received an organ transplant; have received or plan to receive a stem cell transplant that uses donor stem cells (allogeneic); have received radiation treatment to your chest area; have a condition that affects your nervous system, such as myasthenia gravis or Guillain-Barré syndrome.

         

        If you are pregnant or plan to become pregnant, tell your HCP. JEMPERLI can harm your unborn baby. If you are able to become pregnant, your HCP will give you a pregnancy test before you start treatment. Use an effective birth control method during treatment and for 4 months after your last dose of JEMPERLI. Tell your HCP right away if you become pregnant or think you may be pregnant during treatment with JEMPERLI.

         

        If you are breastfeeding or plan to breastfeed, tell your HCP. It is not known if JEMPERLI passes into your breast milk. Do not breastfeed during treatment with JEMPERLI and for 4 months after your last dose.

         

        Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

         

        The most common side effects of JEMPERLI when given with carboplatin and paclitaxel include nerve problems in your arms, hands, legs, and feet; tiredness; nausea; hair loss; joint pain; rash; constipation; diarrhea; stomach-area (abdomen) pain; shortness of breath; decreased appetite; urinary tract infections; vomiting.

         

        The most common side effects of JEMPERLI when used alone include tiredness and weakness, low red blood cell count (anemia), diarrhea, nausea, constipation, vomiting.

         

        These are not all of the possible side effects of JEMPERLI. Call your doctor for medical advice about side effects.

         

        Please see full Prescribing Information, including Medication Guide for patients.

        You are encouraged to report negative side effects of prescription drugs to the FDA.
        Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report negative side effects to GSK at gsk.public.reportum.com or 1-888-825-5249.
        GSK Help Center logo

        Explore the GSK Help Center website to find customer service support and contact information.

        Together with JEMPERLI logo

        If you have questions about how to access or pay for JEMPERLI, visit TogetherwithJEMPERLI.com or call 1-844-4GSK-ONC (1-844-447-5662).